CFLAR and prostate cancer: In addition to reducing the expression of a key regulator of the extrinsic apoptotic pathway like cFLIP, the inhibition of the mevalonate pathway via the treatment of cancer cells with statins may also promote the TRAIL-induced activation of apoptosis by enhancing the expression of apoptotic TRAIL receptors in glioblastoma and prostate cancer cells [20,68].